Clinical trials
Nervous System Diseases clinical trials
Below are recruiting nervous system diseases clinical trials, each written for real people, not researchers. We’re tracking 264 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07077486RecruitingPhase 4
Testing telitacicept vs cyclophosphamide for lupus lung disease
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
Wuhan, HubeiAges 18–80 - NCT05154370Recruiting
Registry for neuroinflammation diseases and diagnosis categories
This study is a registry that collects information from people diagnosed with certain neuroinflammation conditions. It may help doctors learn how these diseases behave over time and support future research.
Beijing, Beijing MunicipalityAges Any age - NCT07315087RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a special type of cell therapy (CAR T-cells) that targets two markers on immune cells, CD19 and BCMA, to calm overactive immune systems in people with certain autoimmune diseases. It's for those whose disease has not been controlled by standard treatments.
TianjinAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT07075185RecruitingPhase 1
Gene therapy study for hard-to-treat multiple myeloma
This study tests a new gene therapy for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The therapy is designed to help your immune system fight the cancer cells more effectively.
Duarte, CaliforniaAges 18 years+ - NCT07413341RecruitingPhase 1
Study of new drug TI-0032-III for hard-to-treat autoimmune diseases
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07167329RecruitingPhase 2
Belzutifan for VHL syndrome: a real-world study
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
São Paulo, São PauloAges 14 years+ - NCT05849467RecruitingPhase 1
Testing how the brain absorbs anti–CD8 therapy in nervous system disease
This Phase 1 study tests a small drug (called an anti–CD8+ T cell minibody) to see how much reaches the brain. It may help researchers understand how to deliver similar treatments for multiple sclerosis, progressive multifocal leukoencephalopathy (PML), or other brain inflammation when the brain’s protective barrier is “open.”
Bethesda, MarylandAges 18–120 - NCT06281093Recruiting
Radio waves and preemies' brain development
This trial checks if radiofrequency fields (like from phones or WiFi) affect the nervous system of preterm babies born between 26 and 34 weeks of pregnancy. It helps us understand if we need to protect these babies from such fields.
Amiens, PicardieAges 1 day–1 month - NCT07390539RecruitingPhase 1
CAR T cells targeting B7-H3 for brain tumors
This trial tests a new type of immune therapy (CAR T cells) that targets a protein called B7-H3 found on some brain tumors. It is for children and young adults with certain brain or spinal cord tumors that have come back after standard treatment, and aims to see if the treatment is safe and effective.
Boston, MassachusettsAges 2–21 - NCT02836158RecruitingPhase 2/Phase 3
Test drug plus spinal chemotherapy for older PCNSL
This trial studies whether adding R-IDARAM and medication delivered into the spinal fluid can improve treatment for primary central nervous system lymphoma (PCNSL) in newly diagnosed older adults. It may help by targeting lymphoma cells in the brain, covering membranes, and spinal fluid.
Beijing, Beijing MunicipalityAges 60–75 - NCT02657785RecruitingPhase 2/Phase 3
Treating newly diagnosed brain lymphoma with added medicines into CSF
This trial studies a treatment plan for people with newly diagnosed non-Hodgkin lymphoma that has spread to the brain and covering tissues (meninges). It combines medicines given through the bloodstream with immunotherapy placed into the fluid around the brain (CSF) to improve control of the lymphoma.
Beijing, Beijing MunicipalityAges 18–75 - NCT04532203RecruitingEarly Phase 1
CAR-T therapy for leukemia or lymphoma in the brain
This early-phase study tests CAR-T cells—immune cells engineered to recognize cancer—for people whose leukemia or lymphoma has spread to the central nervous system (the brain/spinal fluid). It may help shrink or control hard-to-treat (relapsed or refractory) cancers in the brain.
Hangzhou, ZhejiangAges 3–75 - NCT07842835Recruiting
Biosample registry for primary CNS lymphoma
This study collects blood, cerebrospinal fluid, and tumor tissue samples over time from people with suspected or confirmed primary central nervous system lymphoma (PCNSL) in China. The goal is to build a large biobank to better understand the disease and improve future diagnosis and treatment.
Beijing, Beijing MunicipalityAges 18–100 - NCT07839247RecruitingPhase 2
Two oral drugs for brain lymphoma in older adults
This trial tests a combination of two oral medications (zanubrutinib and lenalidomide) for older adults with a certain type of brain lymphoma. The goal is to see if this treatment can help control the disease with manageable side effects.
Beijing, Beijing MunicipalityAges 70 years+ - NCT07827001Recruiting
Monitoring brain tumors during systemic treatment
This study tests whether it's safe to skip radiation and instead rely on a new systemic treatment (like immunotherapy or targeted therapy) to control brain tumors that have spread from other parts of the body. It might help you manage your disease while avoiding the side effects of radiation.
Orange, CaliforniaAges 18 years+ - NCT06554561RecruitingPhase 1/Phase 2
Pomalidomide with rituximab and methotrexate for brain lymphoma
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
Hanzhou, ZhejiangAges 18–75 - NCT06057415Recruiting
Gut nerve stimulation study for high-risk newborns
This study tests whether stimulating the nerves in the gut can help improve digestion in high-risk newborns, specifically those born very early or with a diaphragmatic hernia. It takes place at Amalia Children's Hospital and aims to find a way to help these babies' intestines work better.
NijmegenAges Up to 2 days - NCT07680439RecruitingPhase 2
CAR T cell therapy study for children with DIPG brain tumor
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Los Angeles, CaliforniaAges 1–26 - NCT07634809Recruiting
ADHD Medication Effects on Eye Movement and Nerve Function
This study looks at how ADHD medications affect eye movements and your body's automatic nervous system (which controls heart rate and other functions) in children and teens. Understanding these effects may help doctors use ADHD medications more safely and effectively.
UmeåAges 6–17 - NCT07604987RecruitingPhase 2
New Treatment for Brain Lymphoma (R-PMDT)
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
TianjinAges 18 years+ - NCT07572734Recruiting
Breathing exercises to help after a concussion in teens
This study tests whether special breathing exercises can help the nervous system recover better after a concussion. Kids ages 9–18 who come to the emergency room within 3 days of a concussion may qualify if they have symptoms like dizziness, nausea, tiredness, confusion, anxiety, or sleep problems.
Montreal, QuebecAges 9–18 - NCT06490822Recruiting
Skin study for frontotemporal lobe degeneration
This study looks at whether skin samples can help detect brain changes in people with frontotemporal lobe degeneration (a type of dementia) and related conditions. It compares skin from patients and healthy volunteers to find clues that might help with diagnosis.
NantesAges 50–75
Hear when a new Nervous System Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nervous system diseases?
- Yes. Clin2 currently lists 264 recruiting nervous system diseases studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nervous system diseases trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nervous system diseases trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.